SensoDetect addresses recent share-price volatility and reaffirms accelerating execution, market positioning and strategic financial direction

SensoDetect AB today addresses recent share-price volatility and reaffirms the Company’s accelerating execution, strengthening market position and increasingly favourable financial trajectory. The Company emphasises that the recent movement in share price stands in stark contrast to the strategic and operational progress being achieved across China, Saudi Arabia and Sweden.

-----------------------------------------------------------------------------------------------------------------------------------------------

Over recent months, SensoDetect has materially strengthened its operational platform and commercial readiness by

These developments significantly elevate SensoDetect’s market readiness and commercial potential heading into 2026.

-----------------------------------------------------------------------------------------------------------------------------------------------

The Company’s China strategy is now moving from foundation to controlled acceleration.

Core pillars now advancing

The Company’s leadership in China underscores confidence, momentum and strategic alignment.

-----------------------------------------------------------------------------------------------------------------------------------------------

Discussions with leading healthcare authorities in Saudi Arabia are progressing with a shared strategic objective

SensoDetect views Saudi Arabia as a central market within its global scale strategy.

-----------------------------------------------------------------------------------------------------------------------------------------------

SensoDetect continues to execute with a strict performance-driven financial philosophy based on

Internal modeling signals a strengthening financial trend-line into 2026, with momentum expected to increase further into 2027.

-----------------------------------------------------------------------------------------------------------------------------------------------

CEO Statement – PA Hedin

“We are executing a very clear strategy. While the market has been volatile in the short term, our direction, our milestones, and our momentum have never been clearer. Across China, Saudi Arabia and Sweden, SensoDetect is building a scalable, high-integrity commercial platform. 2026 is designed as the year where structures convert into commercial outcomes, and 2027 is designed as the acceleration phase. I want to thank our long-term shareholders for their confidence. We are entering this next phase determined, focused and with a long-term mindset.”

-----------------------------------------------------------------------------------------------------------------------------------------------

SensoDetect is sharply focused on executing the next phase of its growth plan:

SensoDetects management firmly believes the Company’s fundamental value will become increasingly visible as these initiatives convert into measurable commercial progress.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04
pa.hedin@sensodetect.com

SensoDetect AB is a MedTech AI company listed on the Spotlight Stock Market, focused on establishing the global standard for objective neuro-auditory brain screening. The company’s technology is based on more than 30 years of research in clinical psychoacoustics and neuroscience from Lund University and is protected by a strong international patent portfolio.

SensoDetect’s core platform uses brainstem auditory response patterns to objectively measure neural function in minutes. The method supports large-scale screening and clinical decision-making in conditions such as ADHD, autism spectrum disorder and other neurodevelopmental and psychiatric conditions—providing measurable signals where traditional diagnostic tools rely heavily on subjective assessment.

In recent years, the company has advanced from research to commercial deployment through strategic partnerships and clinical programs in Europe, the Middle East, and China. The latest generation of the system, including BERA 4.2 and integrated AI analysis, enables faster testing, greater scalability, and the ability to support national-level screening initiatives in healthcare, schools, and preventive medicine.

SensoDetect’s mission is to increase diagnostic accuracy, reduce waiting times, and support healthcare systems in managing the rapidly growing global need for mental and neurodevelopmental health evaluation. The company aims to make objective brain screening accessible at scale—improving outcomes for patients, families, and society.

More info at https://www.sensodetect.com/